PORTLAND, Ore. – March 25, 2009 – HemCon today announced results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of Onychomycosis, the most common type of fungal nail infection. The studies were conducted as part of HemCon’s continued program of development for a formulation based on its newest proprietary Mycosinate™ platform technology. The Onychomycosis treatment, Mycosinate™ (formerly known as compound A31S), is available for commercial license and provides a controlled release broad spectrum antimicrobial agent to fight infection.
The independent testing of Mycosinate™ for the treatment of Onychomycosis was performed using fungal infected human nails under conditions that simulate the clinical situation. This system tests the formulations ability to penetrate the nail and kill the T. rubrum fungal infection on human nails over a period of time. Results released in February observed complete kill of the fungal infection in 14 days. The latest study results indicate that cell viability of the infecting organism (T.rubrum) was reduced to 52 percent on day 3 of treatment and further reduced to 5.3 percent on day 7 of treatment with the active Mycosinate™ formulation. A complete kill of the infection was observed at day 14 of treatment. These results contrast favorably with publicly available results for commercially marketed terbinafine, amorolfine and ciclopirox based formulations.
Fungal nail infections affect tens of millions of people worldwide and the market size for its treatment for products is estimated at approximately US$4 billion. It is believed that 6-8 percent of all adults will acquire a fungal nail infection, and Onychomycosis accounts for nearly 50 percent of all nail disorders.
“HemCon’s fourth study in live human nail infection further validates the superior abilities of Mycosinate™, compared to solutions on the market, to safely and effectively treat the millions of people afflicted with fungal nail infections,” said John W. Morgan, CEO of HemCon.
“This innovative platform to treat nail infections provides us with a promising technology in a robust and growing market.”
About HemCon Medical Technologies Inc.
HemCon Medical Technologies Inc, is a leading global developer of advanced medical products designed to improve the standard of patient care. The company is responsible for developing the chitosan-based HemCon® Bandage used by thousands of military and civilian first responders and is changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances including Lyophilized Human Plasma and Nanospider™ technologies. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland; England; Germany and the Czech Republic. For more information, please visit
www.hemcon.com.
Click to expand...